Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Page 1
MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy.
J Exp Clin Cancer Res. 2020 Sep 22;39(1):198. doi: 10.1186/s13046-020-01711-x.
J Exp Clin Cancer Res. 2020.
PMID: 32962738
Free PMC article.
Review.
RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
Weng TH, Yao MY, Xu XM, Hu CY, Yao SH, Liu YZ, Wu ZG, Tang TM, Fu PF, Wang MH, Yao HP.
Weng TH, et al.
Cancer Res Treat. 2020 Jul;52(3):973-986. doi: 10.4143/crt.2019.726. Epub 2020 Apr 22.
Cancer Res Treat. 2020.
PMID: 32324988
Free PMC article.
Item in Clipboard
Cite
Cite